Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given a consensus rating of "Buy" by the eight ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $79.57.
NGNE has been the topic of a number of research analyst reports. Canaccord Genuity Group lowered their price target on Neurogene from $180.00 to $166.00 and set a "buy" rating on the stock in a report on Wednesday, August 12th. William Blair raised shares of Neurogene to a "strong-buy" rating in a report on Wednesday, September 23rd. Guggenheim lifted their price objective on shares of Neurogene from $69.00 to $81.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. HC Wainwright lowered their target price on shares of Neurogene from $65.00 to $60.00 and set a "buy" rating on the stock in a report on Tuesday, November 10th. Finally, JPMorgan Chase & Co. started coverage on shares of Neurogene in a research report on Thursday, October 8th. They set an "overweight" rating and a $60.00 target price for the company.
Check Out Our Latest Stock Report on Neurogene
Neurogene Stock Performance
Shares of Neurogene stock traded up $0.03 during trading on Friday, hitting $23.93. The company's stock had a trading volume of 193,615 shares, compared to its average volume of 312,797. The company has a fifty day simple moving average of $28.21 and a two-hundred day simple moving average of $28.08. The company has a market capitalization of $495.35 million, a PE ratio of -4.70 and a beta of 1.75. Neurogene has a 52 week low of $15.93 and a 52 week high of $43.66.
Neurogene (NASDAQ:NGNE - Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.31. As a group, analysts predict that Neurogene will post -5.26 EPS for the current year.
Institutional Investors Weigh In On Neurogene
Several institutional investors have recently made changes to their positions in NGNE. Marshall Wace LLP bought a new position in Neurogene in the 3rd quarter valued at $4,688,000. Empowered Funds LLC bought a new stake in shares of Neurogene during the third quarter worth $349,000. State Street Corp boosted its stake in shares of Neurogene by 22.4% during the third quarter. State Street Corp now owns 549,269 shares of the company's stock valued at $15,281,000 after purchasing an additional 100,625 shares during the period. Keybank National Association OH purchased a new stake in shares of Neurogene during the third quarter valued at $221,000. Finally, Alps Advisors Inc. boosted its stake in shares of Neurogene by 65.4% during the third quarter. Alps Advisors Inc. now owns 26,528 shares of the company's stock valued at $738,000 after purchasing an additional 10,488 shares during the period. Institutional investors own 52.37% of the company's stock.
Latest Neurogene News
Investors following NGNE have been watching these news items:
- Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share estimates, projecting narrower losses across the periods and lifting its FY2027 estimate to a loss of $4.80 per share from $4.99. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast for Neurogene
- Positive Sentiment: Canaccord Genuity also reaffirmed its Buy rating on Neurogene, signaling continued analyst confidence. Canaccord Genuity keeps Buy rating
- Negative Sentiment: Despite the improved estimates, HC Wainwright still expects Neurogene to report losses in 2026 and 2027, underscoring its ongoing financial risk.
Neurogene Company Profile
(
Get Free Report)
Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company's lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
